Default object view. Click to create a custom template, Node ID: 108164, Object ID: 65180

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients wi...

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

No relation

Yes

No relation

No

21/04/2015 6:14 pm

No